Life Sciences Tools and Services
Company Overview of Personalis, Inc.
Personalis, Inc. provides human genome analysis services for clinical medicine. It offers genome sequencing and interpretation services for research and medical communities. The company was incorporated in 2011 and is based in Palo Alto, California with a subsidiary operation in the United Kingdom.
530 Lytton Avenue
Palo Alto, CA 94301
Founded in 2011
Key Executives for Personalis, Inc.
Co-Founder, Chief Executive Officer and Director
Compensation as of Fiscal Year 2015.
Personalis, Inc. Key Developments
Personalis, Inc. Receives Contract from US Department of Veterans Affairs for Clinical Cancer Genomic Testing and Research Analysis
Mar 19 15
Personalis, Inc. announced that the company has been awarded a contract to provide research and clinical genomic testing for cancer tumors and biopsies, by the US Department of Veterans Affairs (VA) New England Veterans Integrated Service Network 1 (VISN 1) Precision Oncology Program. Personalis will perform clinical cancer testing and research services based on its ACE Extended Cancer Panel for DNA and RNA Analysis. This provides comprehensive and detailed genomic profiling of solid tumors and identification of potential targeted treatment options for VA New England Healthcare System patients. By combining DNA and RNA analysis, and covering over 1,500 genes, Personalis™ testing provides comprehensive data for both clinical testing and ongoing research use at the VA. To further support the VISN 1 Precision Oncology Program and its research goals, Personalis is also providing its ACE Exome for Cancer Research and its ACE Whole Transcriptome for Cancer Research, again pairing DNA with RNA analysis. Personalis will process this sequencing data using its proprietary cancer informatics pipeline. Personalis has also subcontracted N-of-One, Inc, to augment clinical reporting with additional curation. The program plans to begin with samples from Non-Small-Cell Lung Cancer patients, and later expand to other cancer types.
Personalis, Inc. Introduces New Services for Cancer Research and Clinical Trials
Oct 20 14
Personalis, Inc. announced it is launching an expanded portfolio of cancer research solutions based on its ACE (Accuracy and Content Enhanced) sequencing, informatics and content technology platform. Scientists from Personalis presented the new portfolio of cancer research solutions this weekend to attendees at the 2014 American Society of Human Genetics Annual Meeting taking place through Wednesday in San Diego. The ACE Exome for Cancer provides data from the common gene set in the broader context of more than 8,000 medically related genes with augmented coverage, and 20,000 genes overall. The ACE Extended Cancer Panel targets the same broad cancer gene set, but achieves over 500x average sequencing coverage, for optimum sensitivity to alleles from rare cell subpopulations. Personalis offers this end-to-end service starting with a broad range of sample types, including FFPE blocks, Fine Needle Aspirates, core biopsies and fresh frozen tissue. By combining DNA and RNA analysis, Personalis provides a comprehensive tumor genomic profile. DNA and RNA assays are matched to cover the same gene sets, either at the exome level or the panel level. Personalis' cancer data analysis pipeline integrates the DNA and RNA results, providing a more comprehensive understanding than would be possible from either independently. This includes detection of fusion transcripts and allelic expression, as well as gene expression. None of these would be well reported with DNA analysis alone.
Personalis Launches Third Generation ACE Clinical Exome(TM) Test
Oct 17 14
Personalis, Inc. announced the launch of its newly enhanced ACE Clinical Exome(TM) Test for inherited genetic disease. The new test incorporates advances in the company's assay design, an extensive variant-review process, and the involvement of the company's world-class clinical team. The ACE Clinical Exome Test is based on a full exome, targeting essentially all human genes. Of these, Personalis augments the coverage of more than 8,000 medically associated genes, beginning with 4,600 genes identified by the International Collaboration for Clinical Genomics as being related to Mendelian Disease. Personalis then adds genes that have been more recently associated with Mendelian conditions, as well as genes determined likely to have as-yet undiscovered Mendelian associations. The medically associated gene set includes more than 1,200 genes linked to cancer, and hundreds identified as relevant to pharmacogenomics by PharmGKB(TM), the leading pharmacogenomics database. Greater than 6,000 of the augmented genes in the ACE Clinical Exome Test are finished by Personalis (>99% of exonic bases at >=20X coverage), more than any other commercial test. While early exomes for research discovery were designed to capture just the coding sequences of genes, it has long been recognized that medically reportable content extends beyond the coding regions. Personalis has extended the concept of a 'clinical exome' to capture those disease-associated non-coding regions. The ACE Clinical Exome Test provides coverage for a large number of medically reportable variants in untranslated regions (UTRs), introns and promoter regions.
Similar Private Companies By Industry
Recent Private Companies Transactions
December 16, 2014